GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Mustang Bio Inc.
Mustang Bio is a biotech company specializing in cell and gene therapy for cancer treatment. Its stock price is a venture bet on a breakthrough in this cutting-edge field. The chart reflects high volatility and dependence on clinical trial news.
Share prices of companies in the market segment - Dna
Mustang Bio is a biotech company developing gene and cell therapies for the treatment of blood cancers and rare genetic diseases. We've classified it as a "DNA" company. The chart below shows how the market views the prospects of this breakthrough, yet capital-intensive, area of medicine.
Broad Market Index - GURU.Markets
Mustang Bio is a biotech company developing cell and gene therapies for the treatment of cancer and rare genetic diseases. Its cutting-edge science makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Mustang Bio compares to it.
Change in the price of a company, segment, and market as a whole per day
MBIO - Daily change in the company's share price Mustang Bio Inc.
Mustang Bio, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in gene and cell therapy companies. This metric is a measure of sensitivity to clinical trial data, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Dna
Mustang Bio is a gene therapy company, placing it in one of the most volatile segments of biotech. The chart below shows the average daily risk for this sector. It serves as a barometer for assessing whether MBIO's stock price fluctuations are within the norm for such a cutting-edge and risky industry.
Daily change in the price of a broad market stock, index - GURU.Markets
Mustang Bio is a biotechnology company developing gene and cell therapies. The company's shares are a bet on medical breakthroughs. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Mustang Bio Inc.
For Mustang Bio, Inc., the year-to-date performance is a story of cell and gene therapy development. Its 12-month market cap is entirely dependent on clinical trial data from its CAR-T therapy for brain cancer and "bubble boy." Success in these programs could lead to breakthroughs in the treatment of these serious diseases.
Annual dynamics of market capitalization of the market segment - Dna
Mustang Bio, Inc. is a clinical-stage biotechnology company developing gene and cell therapies. Its stock price is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks inherent in this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mustang Bio is a classic biotech company whose fate is decided in the lab. Its year-over-year performance compared to the S&P 500 tells a story not about economics but about investors' faith in the success of its gene therapy. Any news of progress or setback can send the stock soaring or plummeting, defying any market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Mustang Bio Inc.
Mustang Bio is a biotech company developing gene and cell therapies. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its CAR-T therapy programs is a key event, generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Dna
Mustang Bio is a biotech company developing cell and gene therapies for the treatment of blood cancers and rare genetic diseases. Its research is based on research from leading medical centers. The graph below shows the dynamics of the biotech sector, where gene therapy is one of the most promising areas.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mustang Bio is a biotech company developing gene and cell therapies. Its shares move not in sync with the market, but rather based on the results of clinical trials. The success or failure of a single trial can dramatically change the company's value.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Mustang Bio Inc.
Mustang Bio is a biopharmaceutical company developing cell and gene therapies. Its weekly stock price performance, typical of biotech companies, is entirely dependent on progress in its numerous and risky clinical programs.
Weekly dynamics of market capitalization of the market segment - Dna
Mustang Bio is a biotech company specializing in gene and cell therapy. The chart helps separate the stock's unique reaction to clinical trial news from overall sector sentiment. Is the weekly price movement specific to Mustang Bio or is it an industry trend?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Mustang Bio, Inc. is an oncology biotech company. Its success depends on scientific breakthroughs. This chart clearly shows how often the company's shares move against the broader market in response to research data releases. How immune is it to overall market volatility?
Market capitalization of the company, segment and market as a whole
MBIO - Market capitalization of the company Mustang Bio Inc.
The chart for Mustang Bio shows a bet on cell and gene therapy. The market cap of this company, which is developing CAR-T therapy for blood cancer, reflects investors' faith in the future of personalized medicine. It's a highly volatile curve of scientific hopes and risks.
MBIO - Share of the company's market capitalization Mustang Bio Inc. within the market segment - Dna
Mustang Bio is a biopharmaceutical company specializing in the development of cell and gene therapies for the treatment of cancer and rare genetic diseases. Its market capitalization in the cutting-edge DNA medicine segment reflects the potential of its extensive portfolio. The company's market capitalization reflects its bet that its cutting-edge treatments will be successful and reach patients.
Market capitalization of the market segment - Dna
Mustang Bio is a cell and gene therapy company. How big is this arena? The chart below shows the pulse of the DNA technology sector. Its extreme volatility reflects both the enormous potential for treating cancer and rare diseases, as well as the high risks associated with this cutting-edge medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Mustang Bio chart shows how the market values an integrated cell and gene therapy company. The market cap of the company, which is developing CAR-T therapy for blood cancer, reflects its scientific potential and the enormous investment it has made in clinical trials. This chart is brimming with hope for a breakthrough in oncology.
Book value capitalization of the company, segment and market as a whole
MBIO - Book value capitalization of the company Mustang Bio Inc.
Mustang Bio, a cell and gene therapy company, derives its book value from its tangible assets: its own CAR-T cell manufacturing facility, laboratories, and financial reserves. The chart below shows how the company has invested in building this sophisticated scientific and manufacturing base.
MBIO - Share of the company's book capitalization Mustang Bio Inc. within the market segment - Dna
Mustang Bio, Inc. is a cell and gene therapy company. Its main asset is its own facility in Massachusetts, where it produces CAR-T cells for cancer treatment. This state-of-the-art facility is the physical heart of its technology. The chart shows the company's control over this unique biotech manufacturing infrastructure.
Market segment balance sheet capitalization - Dna
Mustang Bio is a cell and gene therapy company. The pharmaceutical industry, as the chart shows, is capital-intensive. Mustang is a prime example. Its business requires building its own, highly complex and expensive factories to produce its drugs.
Book value of all companies included in the broad market index - GURU.Markets
Mustang Bio's assets are not factories, but an alliance with a leading cancer center and a pilot plant for developing cutting-edge gene and cell therapies for the treatment of blood cancers and immunodeficiencies. Its book value reflects its material resources for this complex research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Mustang Bio Inc.
Mustang Bio is a biotech company developing gene and cell therapies. Its market capitalization is a valuation of its cutting-edge, yet risky, pipeline. The chart shows how investors view its science and its connection to the renowned cancer hospital, City of Hope.
Market to book capitalization ratio in a market segment - Dna
Mustang Bio is a biotech company specializing in cell and gene therapy for cancer treatment. Its value is based on the potential of its cutting-edge developments. The chart shows the high investor valuation of its scientific platform, which is licensed from leading institutions.
Market to book capitalization ratio for the market as a whole
Mustang Bio is a gene and cell therapy company. Its entire value is tied to the success of its cutting-edge cancer treatments. This chart illustrates the extreme premium to book value typical of biotech companies operating at the cutting edge of science.
Debts of the company, segment and market as a whole
MBIO - Company debts Mustang Bio Inc.
Mustang Bio is a biotechnology company specializing in gene and cell therapies. Developing such advanced treatments is one of the most expensive processes in medicine. This chart shows how the company is raising significant funds to finance its clinical trials and build manufacturing facilities for its innovative therapies.
Market segment debts - Dna
Mustang Bio is a clinical-stage biotech company developing gene and cell therapies. These treatments are extremely expensive to develop. This chart shows its financial position, which is entirely dependent on its ability to raise capital to fund its cutting-edge research programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Mustang Bio Inc.
Mustang Bio is a biotech company specializing in gene and cell therapy. This chart shows its financial structure. For a company operating at the cutting edge of science, debt is a huge risk. Funding must come from equity to avoid jeopardizing years of expensive research.
Market segment debt to market segment book capitalization - Dna
Mustang Bio is a biotech company focused on developing cell and gene therapies for cancer treatment. These technologies have the potential to transform medicine, but require massive investment. The chart shows the overall debt burden in the sector, highlighting the enormous financial resources the company requires to advance its cutting-edge research.
Debt to book value of all companies in the market
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies. This is at the cutting edge of medicine. This chart clearly shows that for such cutting-edge, yet uncommercialized technologies, debt financing is unavailable, and the company is entirely dependent on capital from investors who believe in its science.
P/E of the company, segment and market as a whole
P/E - Mustang Bio Inc.
For Mustang Bio, a company developing gene and cell therapies, the P/E ratio is not applicable. The company has no profit, and its valuation on this chart is arbitrary. It is a speculative bet that its cutting-edge treatments for cancer and rare diseases will be successful in clinical trials.
P/E of the market segment - Dna
Mustang Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing gene and cell therapies for the treatment of blood cancers and rare genetic diseases. This chart shows the average valuation for the sector, providing investors with context for evaluating Mustang Bio's cutting-edge technologies.
P/E of the market as a whole
Mustang Bio is a biotech company developing cell and gene therapies for cancer and rare diseases. Its valuation is a pure bet on the success of its scientific platform. It has no connection to the general economic cycles depicted by this chart. Mustang's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Mustang Bio Inc.
Mustang Bio is a biotechnology company focused on developing cell and gene therapies for the treatment of cancer and rare genetic diseases. This chart reflects investor expectations for its clinical programs, including CAR-T therapy. The valuation is based on the long-term potential of these breakthrough treatments.
%20P%2FE%20Mustang%20Bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Mustang-Bio-Inc.&v=1772637830588 "Chart of the company's future (projected) P/E Mustang Bio Inc.")
Future (projected) P/E of the market segment - Dna
Mustang Bio is a clinical-stage biopharmaceutical company specializing in the development of gene and cell therapies for the treatment of cancer and rare genetic diseases. Its valuation relative to other biotechs reflects investor sentiment on its cutting-edge technologies, betting that its CAR-T and gene therapies will prove successful.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772637830589 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Mustang Bio is a biopharmaceutical company developing cell and gene therapies for the treatment of cancer and rare genetic diseases. Its clinical-stage developments are underway. This chart shows the overall risk appetite of investors, which is critical for funding capital-intensive research in cutting-edge medical fields like gene therapy.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772637830612 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Mustang Bio Inc.
Mustang Bio is a biotechnology company focused on developing gene and cell therapies, including CAR-T therapy, for the treatment of cancer and rare genetic diseases. The financial performance shown here reflects the high costs of advanced clinical research.
Profit of companies in the market segment - Dna
Mustang Bio is an oncology company developing cell therapies (CAR-T) and gene therapy. This chart reflects the financial health of the DNA and cell therapy sector. It shows how close these cutting-edge, yet extremely expensive to develop, treatments are to becoming commercially successful and accessible.
Overall market profit
Mustang Bio is a biopharmaceutical company specializing in gene and cell therapy for cancer. This is a cutting-edge, yet risky, field of medicine. The company's value is determined solely by scientific data and clinical trial results. Macroeconomic cycles, as seen in this chart, are irrelevant to MBIO.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Mustang Bio Inc.
Mustang Bio is a biotechnology company specializing in gene and cell therapies for cancer and rare diseases. Its future revenue projections are a long-term bet on the success of its cutting-edge developments. This chart reflects analysts' confidence in the potential of its scientific platform to create breakthrough treatments.
%20profit%20of%20the%20company%20Mustang%20Bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Mustang-Bio-Inc.&v=1772637830663 "Graph of future (projected) profit of the company Mustang Bio Inc.")
Future (predicted) profit of companies in the market segment - Dna
Mustang Bio is a biotechnology company developing cell (CAR-T) and gene therapies for the treatment of blood cancers and rare genetic diseases. The technologies are licensed from leading research centers. This chart shows forecasts for the DNA therapy segment. It illustrates the high risk and enormous potential of breakthrough treatments that could transform medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772637830674 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
For Mustang Bio, a gene and cell therapy company, this chart is an indicator of capital availability. Conducting complex clinical trials requires significant investment. An optimistic economic outlook and investor risk appetite are key factors for its development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772637830678 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Mustang Bio Inc.
Mustang Bio is a company developing cell and gene therapies for cancer treatment. With no commercial products, its valuation, as shown in this chart, is based solely on investors' faith in its scientific developments.
P/S market segment - Dna
Mustang Bio is a biopharmaceutical company focused on developing and commercializing advanced cell and gene therapies for the treatment of cancer and rare genetic diseases. This chart shows the average valuation in the DNA technologies sector. It reflects investor confidence in the life-changing potential of Mustang's developments.
P/S of the market as a whole
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for the treatment of cancer and rare genetic diseases. Its valuation is based on the combined potential of its advanced developments. This chart serves as a contrast to the valuation of speculative biotech companies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Mustang Bio Inc.
Mustang Bio is a biotech company developing gene and cell therapies (CAR-T) for the treatment of cancer and rare diseases. Its valuation is based on the future potential of its developments. The chart shows investors' confidence that its cutting-edge treatments will be successful and generate billions in revenue.
%20P%2FS%20Mustang%20Bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Mustang-Bio-Inc.&v=1772637830715 "The graph of the company's future (projected) P/S Mustang Bio Inc.")
Future (projected) P/S of the market segment - Dna
Mustang Bio is a biotechnology company developing cell and gene therapies for the treatment of cancer and rare genetic diseases. It licenses technologies from leading research centers. This chart shows how investors assess the potential of its pipeline of advanced therapeutics.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772637830739 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
This indicator reflects the market's faith in gene and cell therapies. For Mustang Bio, a company developing treatments for cancer and rare genetic diseases, it's a measure of risk appetite. Market optimism is essential for funding breakthrough, but very expensive, technologies that could save lives.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772637830758 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Mustang Bio Inc.
Mustang Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cell and gene therapies for the treatment of cancer. This chart reflects grant revenue. Future revenue is dependent on the success of clinical trials of its CAR-T cell therapy for hematologic malignancies.
Sales of companies in the market segment - Dna
Mustang Bio is a clinical-stage biotechnology company specializing in the development of CAR-T gene and cell therapies for cancer treatment. This chart illustrates the growth of the gene therapy sector. Mustang Bio is at the forefront of one of the most revolutionary areas in oncology, offering hope to patients with difficult-to-treat blood cancers.
Overall market sales
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company specializing in gene and cell therapy for cancer. Its growth depends on successful research. The overall economic environment, shown in this chart, impacts the availability of capital to finance cutting-edge, but very expensive, medical technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Mustang Bio Inc.
Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for cancer, including CAR-T therapy. Its pipeline is licensed from leading research centers. This timeline reflects analyst expectations for the success of its key clinical programs and the potential of its therapeutic platform.
%20sales%20of%20the%20company%20Mustang%20Bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Mustang-Bio-Inc.&v=1772637830763 "Schedule of future (projected) sales of the company Mustang Bio Inc.")
Future (projected) sales of companies in the market segment - Dna
Mustang Bio is a biopharmaceutical company specializing in the development of gene and cell therapies (CAR-T) for cancer treatment. This chart shows expectations for the DNA technology sector. It illustrates the vast potential and significant risks associated with advanced cancer treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772637830773 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies (CAR-T) for the treatment of cancer. Its future depends on the success of its cutting-edge developments. The overall economic environment, reflected in this chart, impacts the availability of capital to fund expensive and time-consuming gene and cell therapy research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772637830779 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Mustang Bio Inc.
Mustang Bio is a biotech company developing cell and gene therapies for cancer and rare diseases. This chart shows the financial picture during the intensive clinical trial phase. Negative values represent investments in establishing in-house manufacturing and conducting expensive trials.
Market segment marginality - Dna
Mustang Bio is a biopharmaceutical company specializing in the development of gene and cell therapies for the treatment of cancer and rare genetic diseases. For a company in the research stage, this chart serves as a benchmark. It shows the average profitability in the sector, illustrating the potential profitability should their cutting-edge treatments be successful.
Market marginality as a whole
Mustang Bio is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies. This overall market profitability chart is irrelevant to the company. Its future depends solely on the results of clinical trials and the ability to demonstrate the effectiveness of its approach in treating cancer and rare genetic diseases.
Employees in the company, segment and market as a whole
Number of employees in the company Mustang Bio Inc.
Mustang Bio is a biopharmaceutical company developing cell and gene therapies for the treatment of cancer and rare genetic diseases. This chart shows the scientific and clinical teams working on cutting-edge treatments. Their numbers reflect progress in clinical programs.
Share of the company's employees Mustang Bio Inc. within the market segment - Dna
Mustang Bio is a company developing gene and cell therapies, including CAR-T, for cancer treatment. This chart shows the percentage of leading immunologists and cell engineers in this cutting-edge field that the company attracts. It reflects its concentration of scientific talent dedicated to creating personalized treatments.
Number of employees in the market segment - Dna
Mustang Bio is a biopharmaceutical company developing cell therapies (CAR-T) and gene therapies for the treatment of cancer and rare genetic diseases. This graph illustrates how complex "living drugs" are being created at the forefront of medicine, requiring an army of scientists, physicians, and highly skilled technicians to produce and administer them.
Number of employees in the market as a whole
Mustang Bio is another company working in the cutting-edge field of gene and cell therapy. This sector requires massive long-term investment and highly qualified personnel. This graph reflects the entire economy, but its innovative core is formed by companies like Mustang Bio, whose work is shaping the technological future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Mustang Bio Inc. (MBIO)
Mustang Bio is a biotech company specializing in gene and cell therapy (CAR-T). This chart is a classic example of intellectual capital valuation. The company's value is based on market expectations for its development pipeline. The chart demonstrates the high future value the market places on this complex science, per scientist.
%20of%20the%20company%20Mustang%20Bio%20Inc.%20(MBIO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Mustang-Bio-Inc.-MBIO&v=1772637830856 "Chart of market capitalization per employee (in thousands of dollars) of the company Mustang Bio Inc. (MBIO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Mustang Bio is a biotech company developing gene and cell therapies. Its value is based on the potential of its scientific breakthroughs. The chart shows the enormous premium the market can pay for each scientist working at the forefront of medicine. This is a bet investors make on their ability to create a breakthrough drug.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772637830859 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Mustang Bio, Inc. is a biopharmaceutical company specializing in cell and gene therapy for cancer. This chart shows the average market cap per employee, highlighting the enormous value the market is placing on the potential of advanced treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772637830860 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Mustang Bio Inc. (MBIO)
Mustang Bio is a clinical-stage biotech company focused on cell and gene therapy. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company burns through each scientist to conduct R&D in this highly complex field.
%20Chart%20Mustang%20Bio%20Inc.%20(MBIO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Mustang-Bio-Inc.-MBIO&v=1772637830866 "Company Profit Per Employee (in thousands of dollars) Chart Mustang Bio Inc. (MBIO)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Mustang Bio is a biopharmaceutical company developing cell and gene therapies for cancer. It is a subsidiary of Fortress Biotech. Being in clinical development, it is likely to report negative earnings per employee, reflecting the company's significant investment in its scientific team and cutting-edge technologies in anticipation of future breakthroughs.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772637830868 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Mustang Bio (MBIO) is a clinical-stage biotech company developing cell therapy (CAR-T) for blood cancer and gene therapy for rare diseases (Bubble Boy disease). This is an R&D company. This chart shows the average profitability per employee across the market. For MBIO (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772637830889 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Mustang Bio Inc. (MBIO)
Mustang Bio is a clinical-stage immuno-oncology company developing cell therapies. This chart is a glimpse into the future. It reflects the enormous revenue potential if its cancer treatments are successful, which is the primary goal of the entire scientific and clinical team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Mustang-Bio-Inc.-MBIO&v=1772637830892 "Sales chart per company employee Mustang Bio Inc. (MBIO)")
Sales per employee in the market segment - Dna
Mustang Bio is a biotechnology company developing cell (CAR-T) and gene therapies for the treatment of cancer and rare diseases. The company is in the R&D stage. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of Mustang's scientific team.
Sales per employee for the market as a whole
Mustang Bio is a clinical-stage biotech company developing cell and gene therapies (CAR-T) for the treatment of cancer. The company has no commercial products or revenue, which is irrelevant. Their value lies in the potential of their R&D team and their in-house manufacturing facility.
Short shares by company, segment and market as a whole
Shares shorted by company Mustang Bio Inc. (MBIO)
Mustang Bio is a biotech company developing cell (CAR-T) and gene therapies for blood cancers and rare diseases. These are extremely expensive and complex technologies. This chart shows bets that the company will run out of money. "Bears" believe their trials will drag on, and they won't be able to fund their capital-intensive R&D.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Mustang-Bio-Inc.-MBIO&v=1772637830949 "Short Shares Chart for the Company Mustang Bio Inc. (MBIO)")
Shares shorted by market segment - Dna
Mustang Bio, Inc. is a biotech company specializing in cell and gene therapy (CAR-T) for the treatment of blood cancers and rare genetic diseases. This chart reflects the total short position in the gene therapy sector. High values indicate general investor skepticism about the safety, efficacy, or commercialization of these breakthrough, but expensive, technologies.
Shares shorted by the overall market
Mustang Bio is developing advanced gene therapy (CAR-T) for cancer treatment. It's an all-or-nothing technology that requires massive investment. This chart illustrates the overall pessimism. When fear dominates, investors are unwilling to accept binary risks. They are selling off MBIO shares, fearing the company won't be able to fund its expensive trials in a market downturn.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Mustang Bio Inc. (MBIO)
Mustang Bio is a biotech company at the forefront of medicine, developing CAR-T gene therapy for blood cancer. This is a binary bet on the success of their trial. This chart measures the market "temperature," showing when the stock is "overheated" (above 70) in anticipation of a breakout, or "oversold" (below 30) due to delays or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Mustang-Bio-Inc.-MBIO&v=1772637830973 "RSI 14 indicator chart for the company's stock Mustang Bio Inc. (MBIO)")
RSI 14 Market Segment - Dna
Mustang Bio is a biotech company specializing in developing cell and gene therapies (CAR-T) for the treatment of blood cancers and rare genetic diseases. This chart measures the collective excitement in the gene therapy sector. It helps determine whether the entire speculative segment is overheated by expectations.
RSI 14 for the overall market
For Mustang Bio, a biotech company in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MBIO (Mustang Bio Inc.)
Mustang Bio is a biotech company developing in-house cell (CAR-T) and gene therapies for the treatment of blood cancers and rare diseases. This chart shows the analysts' average 12-month forecast. It represents their collective speculative bet on the success of their R&D pipeline, developed in partnership with City of Hope.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MBIO-Mustang-Bio-Inc.&v=1772637830998 "A chart showing analyst consensus forecasts for the expected stock price. MBIO (Mustang Bio Inc.)")
The difference between the consensus estimate and the actual stock price MBIO (Mustang Bio Inc.)
Mustang Bio is a biotech company developing cell (CAR-T) and gene therapies for the treatment of blood cancers and rare diseases. This chart shows the difference between the market valuation and the consensus estimate. It indicates whether experts believe in their R&D portfolio, which was spun out of City of Hope.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MBIO-Mustang-Bio-Inc.&v=1772637831000 "A chart showing the difference between the consensus forecast and the actual stock price. MBIO (Mustang Bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Mustang Bio is an R&D biotech company developing cell (CAR-T) and gene therapies for the treatment of cancer and rare diseases. This is high-risk R&D. This chart reflects analysts' overall expectations for the entire DNA technology sector. It shows whether experts believe in the success of junior biotechs.
Analysts' consensus forecast for the overall market share price
Mustang Bio is a biotech company developing cell (CAR-T) and gene therapies for the treatment of blood cancers and rare genetic diseases. This is a high-risk sector. This chart reflects the overall market "risk appetite." For MBIO, a clinical-stage company, overall market optimism (risk appetite) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Mustang Bio Inc.
Mustang Bio is a biotech incubator for Fortress, their subsidiary focused on cell and gene therapy (CAR-T, CRISPR) for complex cancers (brain, blood). This chart is a clear indicator of faith in their (very risky) R&D. It reflects their (slow) progress in clinical trials and their total dependence on funding.
AKIMA Market Segment Index - Dna
Mustang Bio (MBIO) is a biopharmaceutical company developing cell and gene therapies in a single package. They focus on CAR-T therapy for blood cancers and gene therapy for rare cystic fibrosis diseases (SCIDs). The chart shows the segment average, helping investors assess how this high-tech R&D strategy compares to the industry average.
The AKIM Index for the overall market
Mustang Bio is a biotech company developing cell and gene therapies for cancer and rare genetic diseases. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop critical to funding this complex scientific platform.
